APOE and Alzheimer disease: Only biomarker analysis of Aβ peptides and tau may not be sufficient to elucidate the complex cellular, biochemical, genetic (e.g., neprilysin and Apoε4), and metabolic cascades ultimately predisposing TBI victims to an increased risk for AD.